MBX Biosciences, Inc. (MBX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Peter Kent Hawryluk MBA | CEO, President & Director | 788.3k | -- | 1969 |
| Mr. Richard B. Bartram CPA | Chief Financial Officer | 642k | -- | 1981 |
| Dr. Salomon Azoulay M.D. | Chief Medical Officer | 520.51k | -- | 1958 |
| Mr. Matt Gambino | Vice President of Marketing | -- | -- | -- |
| Ms. Michelle Graham | Chief Human Resources Officer | -- | -- | 1967 |
| Dr. Michael A. Dorato DABT, Ph.D. | Sr. Vice President of Discovery & Non-Clinical Development | -- | -- | -- |
| Dr. Chatan Charan Ph.D. | Senior VP of Pharmaceutical Development & Chemistry, Manufacturing and Controls | -- | -- | -- |
| Mr. Mark Hope | Senior Vice President of Regulatory & Quality | -- | -- | -- |
MBX Biosciences, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 43
Description
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Corporate Governance
Upcoming Events
May 12, 2025 at 12:00 PM UTC
MBX Biosciences, Inc. Earnings Date
Recent Events
August 30, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission